As a public health professional, I want people to have access to the health care they need to improve their quality of life. For years I researched available treatments for specific illnesses to determine their safety and efficacy, growing to become an advocate for the development of new treatments for those living with rare diseases.
Yet, for too long, I had no idea the Food and Drug Administration convenes groups of experts, known as advisory committees or ad comms, to review trial data for treatments and make recommendations to inform the FDA’s regulatory decision-making. There are 50 technical and scientific ad comms, made up of more than 200 people, across the FDA. They review the safety and efficacy of medical products.
Even if members of the public don’t know about ad comms, they depend on these expert recommendations, which heavily influence the FDA’s final decision to approve or reject a new treatment.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in